The ε perturbation around the Migdal transformation proposed by Martinelli and Parisi has been computed up to second order for the Ising model in two dimensions on a triangular lattice. Perturbation ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
DNA Ginkgo Bioworks Holdings, Inc.
Valerie is a seasoned writer and editor who has spent her career creating content in the parenting and women's wellness spaces. Before joining Forbes Health, Valerie was the trending news editor at ...
C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...
Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Suzanne is a content marketer, writer, and fact-checker. She ...
Despite his title disappointment, Oscar Piastri says he is determined to regain the feeling he felt at times during his 2025 F1 campaign Lando Norris said made changes in the autumn ‘to unlock more of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback